Genomic Health Announces Study Establishing the Utility of Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated with Aromatase Inhibitors

December 13, 2008

SAN ANTONIO, Dec. 13 /PRNewswire-FirstCall/ — Genomic Health, Inc.
(Nasdaq: GHDX) today announced findings from a European study demonstrating
that the Oncotype DX Recurrence Score(R) result is a significant independent
predictor of distant recurrence in both node-negative and node-positive,
hormone receptor-positive breast cancer patients who are treated with the
aromatase inhibitor anastrozole or with tamoxifen. Researchers from the
Royal Marsden Hospital in London discussed results today in an oral
presentation at the 31st Annual San Antonio Breast Cancer Symposium.

Oncotype DX is a multi-gene expression test that physicians currently use
to predict the likelihood of chemotherapy benefit as well as the likelihood of
recurrence for women with early stage breast cancer. In this prospectively-
designed study, researchers used Oncotype DX to analyze tumor samples from
1,231 patients in the ATAC (Arimidex(R), Tamoxifen, Alone or in Combination)
trial, a landmark study that established the wide use of aromatase inhibitors
for adjuvant treatment of postmenopausal women with hormone receptor-positive
breast cancer.

“Our multivariate analysis confirms that along with other standard
measures such as tumor size, Oncotype DX contributes independently to
providing a more complete picture of prognosis,” said Mitch Dowsett, Ph.D.,
Royal Marsden Hospital and Team Leader at the Breakthrough Breast Cancer
Research Centre in London. “Physicians can take this information into account
when making chemotherapy treatment decisions for both node-negative and node-
positive early stage breast cancer patients planned for either anastrozole or
tamoxifen treatment.”

The study assessed 9-year distant recurrence for women in the anastrozole
and tamoxifen monotherapy arms of the ATAC trial, including patients with
disease that had spread to the lymph nodes (0 nodes, 1-3 nodes and more than 4
nodes). Researchers, with support from the UK’s leading breast cancer
charity, Breakthrough Breast Cancer, and AstraZeneca, collected tumor blocks,
mainly from patients in the United Kingdom, and tested the significance of
adding the Recurrence Score result to a clinical model consisting of age,
tumor size, grade and treatment, as well as the Adjuvant! Online risk
assessment tool.

The study indicated that the Oncotype DX Recurrence Score (RS) result
showed statistically significant prognostic value beyond that provided by
Adjuvant! Online in both node-negative (p<0.001) and node-positive (p=0.003)
patients. The greater efficacy of anastrozole observed in the parent ATAC
trial and the similar hazard ratios for the RS in both treatment arms from
this study suggests a lower risk of recurrence in patients treated with
aromatase inhibitors. In addition, for any RS result, the likelihood of
distant recurrence increases with the number of positive nodes.

“This study is the largest that Genomic Health has conducted to date,
reinforcing our commitment to continue adding value to the Oncotype DX breast
cancer assay by studying additional patient populations and treatment regimens
relevant to current clinical practice,” said Steven Shak, M.D., chief medical
officer of Genomic Health. “These results, combined with the suite of
clinical evidence that we and our clinical partners generated over the past
five years, reinforce our belief that Oncotype DX is an indispensable tool
when making treatment decisions for node-negative patients and in certain
node-positive patients.”

Earlier this week, Genomic Health and research collaborators presented
three additional studies. Highlights include:

    *    An oral presentation on Thursday, December 11 suggested that
         GRB7-dependent pathways are potential therapeutic targets for
         triple-negative breast cancer, a subtype that does not express genes
         for estrogen receptor (ER), progesterone receptor (PR) or HER2.
         Triple negative breast cancer is considered to be more aggressive
         and difficult to treat than hormone receptor-positive or HER2-
         positive breast cancers. These results need to be confirmed with
         future trials.
    *    On Friday, December 12 researchers from Genomic Health presented
         results from a study that demonstrated quantitative RT-PCR analysis
         is possible in ductal carcinoma in situ (DCIS) that is adjacent to
         invasive ductal carcinoma (IDC).  Of the 30 ER-positive breast
         cancer tumor samples that were identified, 90 percent had sufficient
         RNA for Oncotype DX analysis, after separating the DCIS and IDC
         tissues.  While DCIS adjacent to invasive breast cancer demonstrated
         similar quantitative biology for the genes evaluated in the Oncotype
         DX assay, future studies to evaluate Oncotype DX and recurrence
         rates in DCIS are needed.
    *    A separate study, also presented on Friday, December 12, found that
         multiple single nucleotide polymorphisms (SNPs) in the genes that
         encode ER were not associated with the level of ER expression in
         breast cancer, suggesting that differences in ER expression between
         individual tumors are likely a result of factors other than
         inherited gene mutations.

About Oncotype DX(R)

Oncotype DX is the first and only multi-gene expression test commercially
available that has clinical evidence validating its ability to predict the
likelihood of chemotherapy benefit as well as recurrence in early-stage breast
cancer. Additionally, the test report provides quantitative scores for
certain individual genes. Oncotype DX has been extensively evaluated in eleven
clinical studies involving more than 4,000 breast cancer patients, including a
large validation study published in The New England Journal of Medicine and a
chemotherapy benefit study published in the Journal of Clinical Oncology. To
date, 7,500 physicians have ordered more than 75,000 tests, and both Medicare
and private health plans covering approximately 90 percent of U.S. insured
lives provide reimbursement for Oncotype DX through contracts, agreements or
policy decisions. Both the American Society of Clinical Oncology (ASCO) and
the National Comprehensive Cancer Network recommend the use of Oncotype DX for
patients with node- negative breast cancer that is estrogen-receptor positive
and/or progesterone- receptor positive. For more information about Oncotype
DX, please visit http://www.oncotypedx.com.

About Genomic Health

Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on
the development and commercialization of genomic-based clinical laboratory
services for cancer that allow physicians and patients to make individualized
treatment decisions. In 2004, Genomic Health launched its first test,
Oncotype DX(R), which has been shown to predict the likelihood of breast
cancer recurrence and the likelihood of chemotherapy benefit in a large
portion of early-stage breast cancer patients. The company was founded in
2000 and is located in Redwood City, California. For more information, please
visit http://www.genomichealth.com.

About The Royal Marsden Hospital

The Royal Marsden Hospital was the first hospital in the world dedicated
to cancer treatment and research into the causes of cancer. Today the
hospital, which is based in London and in Sutton, sees over 40,000 patients
from the UK and abroad each year. A world leader in research, drug trialing
and diagnostics, The Royal Marsden provides inpatient, day care and outpatient
services for all areas of cancer treatment.

About Breakthrough Breast Cancer

Breakthrough Breast Cancer is the UK’s leading breast cancer charity
committed to fighting breast cancer through research, campaigning and
education. In 1999 Breakthrough established the UK’s first dedicated breast
cancer research centre. The Breakthrough Toby Robins Breast Cancer Research
Centre is housed in the Mary-Jean Mitchell Green building at The Institute of
Cancer Research and was set up in association with the Royal Marsden Hospital
in London. The centre is led by Professor Alan Ashworth FRS. For more
information about Breakthrough Breast Cancer, please visit

Forward-looking Statements

This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995, including statements
relating to the company’s belief that conducting studies in additional patient
populations and treatment regimens adds value to the Oncotype DX breast
cancer assay, the company’s belief that clinical evidence and the results of
the study reinforce that Oncotype DX is an indispensable tool when making
treatment decisions for node-negative and certain node-positive breast cancer
patients, and the conclusions from studies needing additional trials or
research and the ability of the company to conduct such studies or research .
These risks and uncertainties include, but are not limited to: the results of
additional clinical studies; the applicability of clinical study results to
actual outcomes; the risk that the company may not obtain sufficient levels of
reimbursement for any future tests it may develop; the company’s ability to
develop and commercialize new products; the risks and uncertainties associated
with the regulation of the company’s tests by FDA; the company’s ability to
obtain capital when needed; the company’s history of operating losses and the
other risks set forth in its filings with the Securities and Exchange
Commission, including the risks set forth in the company’s Quarterly Report on
Form 10-Q for the three-month period ended September 30, 2008. These forward-
looking statements speak only as of the date hereof. Genomic Health disclaims
any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score
are trademarks or registered trademarks of Genomic Health, Inc. All other
trademarks and service marks are the property of their respective owners.

SOURCE Genomic Health, Inc.

Source: newswire

comments powered by Disqus